Americas
4 November 2025 Merck Serono has failed to convince a US appeals court to overturn a PTAB decision invalidating two dosing regimen patents for cladribine.
3 November 2025
31 October 2025
30 October 2025
Latest Features
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips.
Americas
Being a lawyer with ADHD is far from easy due to widespread misconceptions about the condition but there are ways to offer support, says Lisa Mueller of Casimir Jones.
Americas
Brazil’s updated regulations for its flagship partnerships programme marks a renewed effort to strengthen the nation's health sector, says Rob Rodrigues of RNA Law.
Americas
An ambiguous decision by the Supreme Court has paved the way for frivolous petitions for compensation and clarity is needed, say Daniel Sanchez and Karla Olvera of Olivares.
Americas
Securing IP protection in Brazil for the ‘bio-ink’ used to print new human tissue has challenges but composition is key, say Priscila Kashiwabara and Breno Souza of Kasznar Leonardos.
Americas
If the right steps are taken, the US International Trade Commission is an attractive option for firms fearing the loss of their valuable IP, say Mary Prendergast, Mark Whitaker and Nicole Ang of Morrison Foerster.
Americas
In part 2 of articles assessing the impact of 'Cellect v Samsung', Vincent Shier of Haynes Boone now sets out what the future may hold—both for this unusual case, as well as judicial doctrine in general.
More News
27 October 2025 As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.
24 October 2025 A panel of experts at LSPN shared how AI is forcing companies to rethink everything from obviousness arguments to the choice between patents and trade secrets, and why the claims filed today may be invalid tomorrow.
22 October 2025 The Supreme Court’s 2023 Amgen ruling turned patent strategy upside down. Now lawyers are rethinking everything they thought they knew about protecting inventions. Marisa Woutersen reports from LSPN North America–Fall.
22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
22 October 2025 Just weeks into his tenure, USPTO director John Squires is blitzing US patent policy by taking control of how and when patent challenges can be brought, with proposed rules that could sharply limit repeat and parallel filings. Sarah Speight gauges reaction.
21 October 2025 Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most valuable currency, and why inventorship questions could make or break billion-dollar deals in machine learning.
21 October 2025 LSIPR is gearing up for the 5th annual LSPN North America Fall Conference, starting October 21, in San Francisco, California.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox